NCT04173364View on ClinicalTrials.gov

Interscalene Block and Dysfunction Diaphragmatic

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 29, 2019

Primary Completion Date

September 21, 2020

Study Completion Date

September 21, 2020

Conditions
Diaphragmatic Paralysis
Interventions
DRUG

Ropivacaine 0.5% Injectable Solution

Injectable solution of ropivacaine 0.5%

DRUG

Ropivacaine 0.1% Injectable Solution

Dilution of ropivacaine to the concentration of 0.1%

Trial Locations (1)

Unknown

Hôpital Roger Salengro, CHU, Lille

All Listed Sponsors
lead

University Hospital, Lille

OTHER

NCT04173364 - Interscalene Block and Dysfunction Diaphragmatic | Biotech Hunter | Biotech Hunter